UMIN-ICDS Clinical Trial
| Unique ID issued by UMIN | UMIN000061141 |
|---|---|
| Receipt number | R000069962 |
| Scientific Title | A study on blood component measurements after consumption of the test food-3-: a randomized, double-blind, crossover comparison study |
| Date of disclosure of the study information | 2026/04/02 |
| Last modified on | 2026/04/02 16:53:41 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A study on blood component measurements after consumption of the test food
Acronym
A study on blood component measurements after consumption of the test food
Scientific Title
A study on blood component measurements after consumption of the test food-3-: a randomized, double-blind, crossover comparison study
Scientific Title:Acronym
A study on blood component measurements after consumption of the test food-3-
Region
| Japan |
Condition
Condition
Healthy Japanese
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To verify the time-dependent changes in blood astaxanthin compounds after consumption of the test food.
Basic objectives2
Others
Basic objectives -Others
To verify the time-dependent changes in blood astaxanthin compounds after consumption of the test food.
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
1. The changes in the concentration of astaxanthin compounds in blood
2. Pharmacokinetic parameters
Key secondary outcomes
1. Individuals who experienced adverse events
2. Systolic blood pressure and diastolic blood pressure in Test 1 and Test 2
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Institution is not considered as adjustment factor.
Blocking
YES
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Educational,Counseling,Training
Type of intervention
| Food |
Interventions/Control_1
<Duration>
Single ingestion
<Test food>
Test 1: Test food 1
Test 2: Test food 2
*The intervention sequence is Test 1 followed by Test 2.
*The washout period is at least one week.
Interventions/Control_2
<Duration>
Single ingestion
<Test food>
Test 1: Test food 2
Test 2: Test food 1
*The intervention sequence is test 1 followed by test 2.
*The washout period is at least one week.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Japanese
2. Men or women
3. Adults
4. Healthy individuals
5. Individuals whose BMI is >=18.5 kg/m2 and <25 kg/m2
Key exclusion criteria
1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction
2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator
3. Individuals who are currently receiving treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, chronic kidney disease, cerebrovascular disease, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic disease
4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims
5. Individuals who are taking or using medications (including herbal medicines) or supplements
6. Individuals who are allergic to medications or foods related to the test food
7. Individuals who are pregnant, lactating, or planning pregnancy during this study
8. Individuals who have participated in other clinical studies within 28 days before informed consent, or plan to participate in another study during this study
9. Individuals who have pre-existing gastrointestinal diseases (irritable bowel syndrome, inflammatory bowel disease, gastric ulcer, or gastroesophageal reflux disease)
10. Individuals who are deemed unsuitable for participation in this study by the principal investigator
Target sample size
9
Research contact person
Name of lead principal investigator
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Organization
Medical Corporation Seishinkai, Takara Clinic
Division name
Director
Zip code
141-0022
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
TEL
03-5793-3623
t-takara@takara-clinic.com
Public contact
Name of contact person
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
Organization
ORTHOMEDICO Inc.
Division name
R&D Department
Zip code
112-0002
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
TEL
03-3818-0610
Homepage URL
nao@orthomedico.jp
Sponsor or person
Institute
Life Science Division Fuji Chemical Industries Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Fuji Chemical Industries Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
Tel
03-5793-3623
IRB@takara-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
Other administrative information
Date of disclosure of the study information
| 2026 | Year | 04 | Month | 02 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2026 | Year | 03 | Month | 11 | Day |
Date of IRB
| 2026 | Year | 03 | Month | 11 | Day |
Anticipated trial start date
| 2026 | Year | 04 | Month | 02 | Day |
Last follow-up date
| 2026 | Year | 06 | Month | 20 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2026 | Year | 04 | Month | 02 | Day |
Last modified on
| 2026 | Year | 04 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000069962
